New Agents for Treatment of Lymphomas: Which Ones Will Succeed?
F B Hagemeister, MD, The Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. March 2008

Treanda® plus Rituxan® Effective for Recurrent Non-Hodgkin’s Lymphoma (7/17/2008)
Researchers from Canada and the United States have reported that the combination of Treanda® (bendamustine) plus Rituxan® (rituximab) provides effective therapy for patients with non-Hodgkin’s lymphoma (NHL) that has stopped responding to prior treatment. These results appeared in an early online publication in the Journal of Clinical Oncology on July 14, 2008.

Pegylated Liposomal Doxorubicin Effective for Advanced or Refractory Cutaneous T-cell Lymphoma (7/11/2008)
Researchers from France have reported an overall response rate of 56% in patients with advanced or refractory cutaneous T-cell lymphoma (CTCL) following treatment with pegylated liposomal doxorubicin (Doxil®, Caelyx®). The details of this study appeared in the June 2008 issue of the Archives of Dermatology.

Maintenance Rituxan® Is Safe for Follicular Lymphoma (7/8/2008)
Researchers affiliated with the International IIIb MAXIMA trial have reported that continued treatment for up to two years with Rituxan® (rituximab) is a safe therapeutic approach for the treatment of follicular lymphoma. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology in Chicago June 2-May 30.

Second Tumors Common in Patients with Gastric MALT Lymphoma (7/2/2008)
Researchers from Germany have reported that patients with gastric mucosal associated tissue (MALT) lymphoma have high incidence of second tumors. The results of this 10-year study were reported at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Tricyclic Antidepressants May Increase the Incidence of Non-Hodgkin Lymphoma (7/2/2008)
Researchers from Denmark reported that patients who are long-term takers of tricyclic antidepressant medications have a 53% increased incidence of non-Hodgkin lymphoma (NHL). These data were also published in the July issue of Epidemiology.